These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 564941)

  • 21. Chromium 51 EDTA/technetium 99m MDP plasma ratio to measure total skeletal function.
    Nisbet AP; Edwards S; Lazarus CR; Malamitsi J; Maisey MN; Mashiter GD; Winn PJ
    Br J Radiol; 1984 Aug; 57(680):677-80. PubMed ID: 6235885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relative distribution of diphosphonate between bone and soft tissue at 4 and 24 hours: concise communication.
    Smith ML; Martin W; Fogelman I; Bessent RG
    J Nucl Med; 1983 Mar; 24(3):208-11. PubMed ID: 6402571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Differential diagnosis of osteomalacia and other forms of renal osteodystrophy in terminal renal failure by dynamic scintigraphy with diphosphonate].
    Novikov AI; Ermolenko AE; Ermakova IP; Baeva LB; Levitskiĭ ER
    Ter Arkh; 1989; 61(6):105-9. PubMed ID: 2799693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prominent Tc-99m MIBI skeletal uptake in renal osteodystrophy: a possible role for whole-body scanning.
    Reczek J; Elgazzar A
    Clin Nucl Med; 2003 Sep; 28(9):775-7. PubMed ID: 12973007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Technetium-99m-pyrophosphate kinetics and imaging in metabolic bone disease.
    Rosenthall L; Kaye M
    J Nucl Med; 1975 Jan; 16(1):33-9. PubMed ID: 162946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value of the 99mTc-methylene diphosphonate bone scan in renal osteodystrophy.
    Karsenty G; Vigneron N; Jorgetti V; Fauchet M; Zingraff J; Drüeke T; Cournot-Witmer G
    Kidney Int; 1986 May; 29(5):1058-65. PubMed ID: 3723927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Classification of bone scintigrams in hemodialysis patients].
    Ishibashi K; Miyamae T
    Kaku Igaku; 1985 Mar; 22(3):367-76. PubMed ID: 3160875
    [No Abstract]   [Full Text] [Related]  

  • 28. [Radiological aspects of Paget's disease of bone (author's transl)].
    Maldague B; Malghem J
    J Belge Rhumatol Med Phys; 1974; 29(5-6):293-321. PubMed ID: 4470110
    [No Abstract]   [Full Text] [Related]  

  • 29. [Importance of bone scanning with Tc 99m in the supervision of hemodialysis patients with chronic renal failure (author's transl)].
    Kessler M; Ferry JP; Naoun A; Robert J; Huriet C
    Nephrologie; 1981; 2(4):171-5. PubMed ID: 7329502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paget's disease of bone mimicking metastases.
    Kattapuram SV; Phillips WC
    J Can Assoc Radiol; 1982 Dec; 33(4):239-45. PubMed ID: 6219112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 99Tcm-MDP global skeletal uptake and markers of bone metabolism in patients with bone diseases.
    Rubini G; Lauriero F; Rubini D; D'Addabbo A
    Nucl Med Commun; 1993 Jul; 14(7):567-72. PubMed ID: 8355916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone scintigraphy in metabolic bone disease.
    Ryan PJ; Fogelman I
    Semin Nucl Med; 1997 Jul; 27(3):291-305. PubMed ID: 9224668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum kinetics, bioavailability and bone scanning of 99mTc-labelled sodium olpadronate in patients with different rates of bone turnover.
    Degrossi OJ; Ortiz M; Degrossi EB; García del Río H; Barreira JC; Messina D; Kerzberg E; Roldán EJ; Montuori E; Pérez Lloret A
    Eur J Clin Pharmacol; 1995; 48(6):489-94. PubMed ID: 8582468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deconvolution analysis of 99mTc-methylene diphosphonate kinetics in metabolic bone disease.
    Knop J; Kröger E; Stritzke P; Schneider C; Kruse HP
    Eur J Nucl Med; 1981 Feb; 6(2):63-7. PubMed ID: 6451429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Role of photon absorption densitometry of the bone in uremic osteodystrophy].
    Bichi Secchi E; Baldelli S; Argalia G; Pigini G; Lombardi M; Procaccini G; Bordoni E
    Radiol Med; 1987 Apr; 73(4):265-70. PubMed ID: 3575801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-invasive evaluation of bone formation: measurements of serum alkaline phosphatase, whole body retention of diphosphonate and serum osteocalcin in metabolic bone disorders and thyroid disease.
    Hyldstrup L; Clemmensen I; Jensen BA; Transbøl I
    Scand J Clin Lab Invest; 1988 Nov; 48(7):611-9. PubMed ID: 3264412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole body and regional retention of Tc-99m-labeled diphosphonates with a whole-body counter: a study with normal males.
    Molloi S; Mazess R; Bendsen H; Wilson M
    Calcif Tissue Int; 1989 May; 44(5):322-9. PubMed ID: 2496903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetics of 99mtechnetium-tin-methylene-diphosphonate in normal subjects and pathological conditions: a simple index of bone metabolism.
    Caniggia A; Vattimo A
    Calcif Tissue Int; 1980; 30(1):5-13. PubMed ID: 6767533
    [No Abstract]   [Full Text] [Related]  

  • 39. Nuclear medicine studies in metabolic bone disease.
    Hain SF; Fogelman I
    Semin Musculoskelet Radiol; 2002 Dec; 6(4):323-29. PubMed ID: 12541189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Common roentgen morphology of generalized osteopathies].
    Heuck F
    Radiologe; 1986 Dec; 26(12):563-72. PubMed ID: 3823418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.